Pulse Biosciences, Inc. (PLSE) · Oct 14, 2026 · Material agreement

Pulse Biosciences thyroid partnership starts treatment and data push

Thyroid partnership — Commercial treatment plus real-world and formal clinical data collaboration

Pulse Biosciences’ new thyroid partnership puts Vybrance into Clayman patient care and expands evidence collection, but largely confirms an expected plan.

Pulse Biosciences is moving its nPulse platform through two parallel paths: late-stage cardiac development and early commercial/clinical development of the Vybrance system for thyroid nodules. Before this filing, the company had already completed enrollment in its 100-patient PRECISE-BTN benign-thyroid-nodule study, while its second-quarter update had already disclosed the Clayman partnership.

The partnership is now operational, not merely strategic. Clayman is treating patients with Vybrance under Pulse’s controlled market-development program, giving the company another active treatment site and a high-volume referral center. 〔0〕

The main incremental value is evidence generation, not near-term revenue. The agreement adds real-world outcomes collection and formal clinical studies around benign thyroid nodules, which can help support broader adoption and future access—but it does not report new efficacy results, regulatory expansion, or a material commercial commitment. 〔1〕

Relative to expectations, this is progress but not a surprise. The partnership itself was already disclosed in the company’s second-quarter business update, so today’s filing mostly confirms execution and provides more detail on patient treatment and data collection rather than changing the company’s strategic direction.

Bottom line: This advances Vybrance from planned market development into active use at a prominent thyroid center, but the business impact is incremental because the partnership was already known and no new clinical or financial outcome is reported.

Original filing on SEC EDGAR

More Pulse Biosciences, Inc. news

Pulse Biosciences thyroid partnership starts treatment and data push | PLSE Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.